Press Releases

MYOS RENS Technology to Present at the 9th Annual LD Micro Invitational in Los Angeles, CA

Download PDF

Company Presentation on Tuesday, June 4 at 3:40pm PT to Highlight its Core Nutritional Products

CEDAR KNOLLS, N.J., May 21, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle in conjunction with resistance training, announced today that it will present at the 9th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles being held June 3rd through 5th, 2019. 

(PRNewsfoto/MYOS RENS Technology)

Joseph Mannello, Chief Executive Officer of MYOS, is scheduled to present on Tuesday, June 4th at 3:40pm Pacific Time, and will be available to meet with investors throughout the conference. Mr. Mannello will present an overview of the Company with a focus on Yolked® and MYOS Canine Muscle Formula®, the Company's two core products that are changing the way people think about the importance of muscle health.

Mr. Mannello will be available on Tuesday, June 4 and Wednesday, June 5 for one-on-one meetings. To schedule a meeting, please contact David Scher at or visit for more information.

About MYOS RENS Technology Inc. 
MYOS RENS Technology Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the success of our products, including Qurr®, Yolked®MYOS Enteral Nutrition Formula™ and MYOS Canine Muscle Formula® , the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate revenue and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with  the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:
Porter LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700

Cision View original content to download multimedia:

SOURCE MYOS RENS Technology Inc.